Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSF +15.85%85 Days Sales Outstanding is 40.37 as of Dec. 2025, which is 3% below its 10-year median of 41.64. GuruFocus rates EBOSF with a GF Score™ of 85/100 and a GF Value™ of $43.41. The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Ebos Group ranks better than 83.05% on this metric.
Ebos Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was $1,003 Mil. Ebos Group's Revenue for the
six
months ended in Dec. 2025 was $4,537 Mil.
Hence, Ebos Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 40.37.
The historical rank and industry rank for Ebos Group's Days Sales Outstanding or its related term are showing as below:
EBOSF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.67 Med: 41.64 Max: 56.38
Current: 41.96
During the past 13 years, Ebos Group's highest Days Sales Outstanding was 56.38. The lowest was 38.67. And the median was 41.64.
EBOSF's Days Sales Outstanding is ranked better than 83.05% of 118
companies
in the Medical Distribution industry
Industry Median: 79.025
vs EBOSF: 41.96
Ebos Group's Days Sales Outstanding
declined
from Dec. 2024 (44.27) to Dec. 2025 (40.37).
Ebos Group (OTCPK:EBOSF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ebos Group Days Sales Outstanding Related Terms
Ebos Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ebos Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBOSF vs MCK, COR, CAH: Days Sales Outstanding Comparison
For the Medical Distribution subindustry, Ebos Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Days Sales Outstanding vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ebos Group's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (EBOSF) has a Days Sales Outstanding of 40.37 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ebos Group and its competitors. This is near median its historical median of 41.64. Over the past decade, Ebos Group's Days Sales Outstanding has ranged from 38.67 to 56.38. According to the industry distribution chart, Ebos Group ranks #20 out of 118 companies in the Medical Distribution industry, placing it in the top 16.9%.
Is Ebos Group's Days Sales Outstanding too high?
Ebos Group's current Days Sales Outstanding of 40.37 is near median its 10-year median of 41.64. Over the past 10 years, this metric has ranged from a low of 38.67 to a high of 56.38. The Medical Distribution industry median Days Sales Outstanding is 79.03. Ebos Group's value of 40.37 is 48.9% below this industry median. Based on the distribution chart, Ebos Group ranks #20 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Days Sales Outstanding compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #20 out of 118 companies for Days Sales Outstanding. This places Ebos Group in the top 17% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 79.03. Ebos Group's value of 40.37 is 48.9% below this benchmark. Historically, Ebos Group's own Days Sales Outstanding has ranged from 38.67 to 56.38 over the past decade. While the company's 10-year median is 41.64 vs. the industry median of 79.03, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Distribution company?
The median Days Sales Outstanding among Medical Distribution companies is 79.03, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Days Sales Outstanding of 40.37 is 48.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Days Sales Outstanding is 79.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Days Sales Outstanding is 40.37, which is near median its own 10-year median of 41.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current Days Sales Outstanding of 40.37. The stock's GF Value™ is $43.41, compared to a current price of $23.75 — trading 45.3% below its estimated fair value. The current Days Sales Outstanding is 40.37, which is near median its 10-year median of 41.64 and 48.9% below the Medical Distribution industry median of 79.03. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ebos Group (EBOSF), the current Days Sales Outstanding is 40.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 45.3% below its estimated GF Value™ of $43.41.
Key valuation signals for EBOSF:
Days Sales Outstanding: 40.37 (near median its 10-year median of 41.64)
GF Value™: $43.41 vs. price of $23.75 (45.3% below fair value)
Industry Position: 48.9% below the Medical Distribution median (#20 of 118)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
